Quarterly ResultMay 11, 2026, 08:46 AM
Adial Pharmaceuticals Q1 Net Loss $2.0M; Advances AD04, Eyes Funding
AI Summary
Adial Pharmaceuticals reported a net loss of $2.0 million for Q1 2026, an improvement from $2.2 million in Q1 2025, driven by lower R&D expenses. The company ended the quarter with $4.6 million in cash, sufficient to fund operations into the second half of 2026. Strategically, Adial is advancing its AD04 program, benefiting from evolving FDA policies that could streamline drug approval and growing support for patient-centered endpoints in Alcohol Use Disorder. The company also established a collaboration framework with Molteni Farmaceutici for European commercialization and strengthened its intellectual property, while actively seeking additional funding.
Key Highlights
- Net loss for Q1 2026 was $2.0 million, down from $2.2 million in Q1 2025.
- Cash and cash equivalents were $4.6 million as of March 31, 2026, funding operations into H2 2026.
- Research and development expenses decreased by 42% to $433 thousand in Q1 2026.
- General and administrative expenses increased by 3% to $1.6 million in Q1 2026.
- FDA policy discussions indicate potential approval with one pivotal study, potentially reducing AD04 development costs.
- Established a collaboration framework with Molteni Farmaceutici for AD04's commercial pathway in Europe.
- International patent application, if granted, is expected to extend AD04 protection through at least 2045.
- Company is actively pursuing financing and strategic alternatives to advance AD04.
Price Impact
More from ADIL